Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ReMATCH Study is a Prospective, Single Arm, Open Label, Multi-center, Study Utilizing the FARAPULSE PFA System, Including the FARAWAVE and FARAPOINT PFA Catheters

NCT06735534 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT06735534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06735534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ReMATCH Study is a Prospective, Single Arm, Open Label, Multi-center, Study Utilizing the FARAPULSE PFA System, Including the FARAWAVE and FARAPOINT PFA Catheters
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Active, not recruiting
Start date
June 3, 2025
Completion date
January 31, 2028
Enrollment
376 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

persistent atrial fibrillation